(4) Policy Briefing: A New Agenda For CMS, The Biden White House, And A Democratic Congress The Certara Market Access Channel podcast

Inhoud geleverd door Certara Evidence & Access and Certara Evidence. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Certara Evidence & Access and Certara Evidence of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

The Certara Market Access Channel »
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress

3+ y ago 20:34

MP3•Thuis aflevering

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.

In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.

Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/

--- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message

4 afleveringen

#Science #Certara Evidence & Access #Certara Evidence